Skip to content

Psilocybin: all studies

Page 73 of 440: studies 721 to 730 of 4,400, newest first. Back to the psilocybin overview

Research

Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation

Journal of Psychoactive Drugs March 14, 2025 Lukas Bobak, Ian Dorney, Alexsandra Kovacevich et al. 2 citations

Long COVID lacks effective pharmaceutical treatment options. Psychedelic treatment for long COVID has received attention given anecdotal reports of neuropsychiatric symptom improvement. This study investigates the use of psilocybin for neuropsychiatric long COVID symptoms, examining online accounts of individuals with reported long COVID using psilocybin. We searched the Reddit communities,...

BIOLOGICAL ACTIVITY OF PSILOCYBIN EXTRACTS FROM THE FRUITING BODIES OF PSILOCYBE CUBENSIS ANTIOXIDANT AND ANTIMICROBIAL POTENTIAL

Journal of Microbiology Biotechnology and Food Sciences March 13, 2025 Shimal Yonuis Abdulhadi, Noor Alaubidi, Walla H. Shuker et al. 1 citation

Several fruiting bodies from Mosul forests were collected and were diagnosed using the Polymerase Chain Technique based on ITS region. It was proved they belong to Psilocybe cubensis mushroom, and was registered in the GenBank, NCBI in the serial number OR140556.1. The fruiting body powder was used in order to extract the alkaloid compound “Psilocybe”, which was analyzed using HPLC technique....

DOI: 10.55251/jmbfs.12097 (opens in new tab) Psilocybin Antimicrobial Antioxidant Traditional medicine +4

PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS

Journal of medical & health sciences review. March 11, 2025 Ahmad Daryani, Muhammad Ali, Usman Ul Haq

Psilocybin, MDMA, and LSD have recently emerged as popular psychedelic substances for use in psychopharmacology in managing various disorders including treatment-resistant depression, PTSD, and anxiety. These substances mainly affect the serotonergic receptors that involve the regulation of consciousness, perceptions, and cognition. These unique alterations in brain connectome show the...

Lasting effect of psilocybin on sociability can be blocked by DNA methyltransferase inhibition

bioRxiv (Cold Spring Harbor Laboratory) March 11, 2025 Chenchen Song, Tinya Chang, Tobias Buchborn et al. 4 citations preprint

Abstract The recent renaissance in research on psychedelics such as psilocybin has highlighted their therapeutic potential including their lasting influences on brain function. Here we report that a single systemic administration of the serotonergic psychedelic psilocybin can durably promote social behaviour in the Cntnap2-knockout mouse model of autism. This effect can be blocked by...

Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression

bioRxiv (Cold Spring Harbor Laboratory) March 10, 2025 Shaun K.l. Quah, Cameron C. Glick, Leor Roseman et al. preprint

Abstract Major Depressive Disorder (MDD) is typically characterized by altered linear functional connectivity (FC) across large-scale brain networks. Yet, it is unclear whether similar alterations are observed when nonlinear FC is examined. This study investigated how antidepressant treatment (i.e., psilocybin and escitalopram) modulates both linear FC and nonlinear FC in individuals with MDD....

DOI: 10.1101/2025.03.05.641592 (opens in new tab) Full text (opens in new tab) Psilocybin Escitalopram Functional connectivity Depression economics +4

Risks of using psilocybin in treatment of treatment-resistant depression

Journal of Education, Health and Sport March 7, 2025 Michał Orzechowski, Joanna Orzechowska, Paulina Fijałek et al.

Introduction As depression rates continue to rise globally, the need for more effective and innovative treatments has become increasingly urgent, highlighting the potential impact of psilocybin as a promising therapeutic option. However, to ensure its safe and effective integration into clinical practice, it is essential to establish robust safety parameters for its administration. This paper...

DOI: 10.12775/JEHS.2025.79.58319 (opens in new tab) Full text (opens in new tab) Treatment resistant depression Safety Psychedelic assisted therapy Adverse effects +1

Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes

Neuropharmacology March 7, 2025 Stefan Modzelewski, Anna Stankiewicz, Napoleon Waszkiewicz et al. 5 citations

This review is limited by the heterogeneity in reporting side effects and the short duration of many studies. Future studies should transparently and systematically present a description of side effects.

Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications

Pharmaceuticals March 7, 2025 Taynah P Galdino, Lucas C Oliveira, Mateus A Luz et al. 11 citations

The growing body of evidence supporting the therapeutic efficacy of psychoactive substances, like psilocybin, has driven significant interest in recent decades due to their low toxicity and potential applications in treating various mental health disorders. However, producing pharmaceutical-grade psilocybin remains challenging, with three primary approaches: chemical synthesis, biosynthesis,...

DOI: 10.3390/ph18030380 (opens in new tab) Extraction methods Psychoactive compounds Yield optimization Extraction techniques +3

Psilocybin therapy might help frontline pandemic workers

The Brown University Psychopharmacology Update March 3, 2025

The stressors that frontline healthcare workers experienced during the COVID-19 pandemic led to widespread burnout, depression, and post-traumatic stress disorder (PTSD). Based on research showing that psychedelic-assisted therapy led to improvement in symptoms of depression in various populations, investigators conducted a randomized clinical trial to evaluate the effects of psilocybin therapy...